IL205501A - Preparation of preparations for the treatment of arthritis - Google Patents

Preparation of preparations for the treatment of arthritis

Info

Publication number
IL205501A
IL205501A IL205501A IL20550110A IL205501A IL 205501 A IL205501 A IL 205501A IL 205501 A IL205501 A IL 205501A IL 20550110 A IL20550110 A IL 20550110A IL 205501 A IL205501 A IL 205501A
Authority
IL
Israel
Prior art keywords
methyl
amino
piperazin
fused
unfused
Prior art date
Application number
IL205501A
Other languages
English (en)
Hebrew (he)
Other versions
IL205501A0 (en
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of IL205501A0 publication Critical patent/IL205501A0/en
Publication of IL205501A publication Critical patent/IL205501A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
IL205501A 2007-11-16 2010-05-02 Preparation of preparations for the treatment of arthritis IL205501A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98847907P 2007-11-16 2007-11-16
PCT/US2008/083478 WO2009064938A1 (en) 2007-11-16 2008-11-14 Method of treating arthritis

Publications (2)

Publication Number Publication Date
IL205501A0 IL205501A0 (en) 2010-12-30
IL205501A true IL205501A (en) 2013-08-29

Family

ID=40291332

Family Applications (2)

Application Number Title Priority Date Filing Date
IL205501A IL205501A (en) 2007-11-16 2010-05-02 Preparation of preparations for the treatment of arthritis
IL227641A IL227641A0 (en) 2007-11-16 2013-07-24 Methods for treating arthritis

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL227641A IL227641A0 (en) 2007-11-16 2013-07-24 Methods for treating arthritis

Country Status (14)

Country Link
US (2) US20090176785A1 (https=)
EP (1) EP2231159A1 (https=)
JP (2) JP5450434B2 (https=)
KR (1) KR101585848B1 (https=)
CN (1) CN101969951B (https=)
AU (1) AU2008322595B2 (https=)
CA (1) CA2705294C (https=)
DO (1) DOP2013000169A (https=)
IL (2) IL205501A (https=)
MX (1) MX2010005395A (https=)
NZ (2) NZ601350A (https=)
RU (2) RU2472509C2 (https=)
WO (1) WO2009064938A1 (https=)
ZA (1) ZA201003434B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2011119345A2 (en) * 2010-03-25 2011-09-29 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI520960B (zh) 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
CA3152557A1 (en) 2010-10-29 2012-05-03 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
PT2643322T (pt) 2010-11-23 2017-11-13 Abbvie Inc Sais e formas cristalinas de um agente indutor de apoptose
TWI620736B (zh) 2010-11-23 2018-04-11 艾伯維巴哈馬有限公司 使用選擇性bcl-2抑制劑之治療方法
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
AU2018322059C1 (en) 2017-08-23 2024-09-12 Guangzhou Lupeng Pharmaceutical Company Ltd. BCL-2 inhibitors
US12220419B2 (en) 2018-08-22 2025-02-11 Newave Pharmaceutical Inc. BCL-2 inhibitors
WO2020140005A2 (en) 2018-12-29 2020-07-02 Newave Pharmaceutical Inc. Bcl-2 inhibitors
WO2021066873A1 (en) 2019-10-03 2021-04-08 Newave Pharmaceutical Inc. Condensed heterocycles as bcl-2 inhibitors
MX2022005375A (es) 2019-11-05 2022-10-07 Abbvie Inc Regímenes de dosificación para usar en el tratamiento de la mielofibrosis y trastornos relacionados con neoplasias mieloproliferativas (nmp) con navitoclax.
WO2021133817A1 (en) 2019-12-27 2021-07-01 Guangzhou Lupeng Pharmaceutical Company Ltd. 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases
KR20220158725A (ko) 2020-02-24 2022-12-01 광조우 루펭 파마슈티칼 컴퍼니 엘티디. Bcl2 억제제를 함유하는 핫 멜트 압출 고체 분산체
WO2022140224A1 (en) 2020-12-22 2022-06-30 Newave Pharmaceutical Inc. 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9200275D0 (en) * 1992-01-08 1992-02-26 Roussel Lab Ltd Chemical compounds
EP0863873B1 (en) * 1995-10-10 1999-11-10 Pfizer Inc. Indole carbamates as leukotriene antagonists
EP1265864A1 (en) * 2000-03-21 2002-12-18 The Procter & Gamble Company Heterocyclic side chain containing, n-substituted metalloprotease inhibitors
DE60137273D1 (de) * 2000-10-20 2009-02-12 Eisai R&D Man Co Ltd Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten
GB0217431D0 (en) * 2002-07-27 2002-09-04 Astrazeneca Ab Novel compounds
CN1856490A (zh) * 2003-07-28 2006-11-01 詹森药业有限公司 苯并咪唑、苯并噻唑和苯并噁唑衍生物及其作为lta4h调节剂的应用
CN1867551B (zh) * 2003-09-03 2013-09-11 拉夸里亚创药株式会社 作为前列腺素e2拮抗剂的苯基或吡啶基酰胺化合物
WO2005049593A2 (en) * 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
ES2257929B1 (es) * 2004-07-16 2007-05-01 Laboratorios Del Dr. Esteve, S.A. Derivados de pirazolina, procedimiento para su obtencion y utilizacion de los mismos como agentes terapeuticos.
EP1888550B1 (en) * 2005-05-12 2014-06-25 AbbVie Bahamas Ltd. Apoptosis promoters
US20060276464A1 (en) * 2005-05-13 2006-12-07 Wyeth Diarylsulfone sulfonamides and use thereof
WO2008064116A2 (en) * 2006-11-16 2008-05-29 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection

Also Published As

Publication number Publication date
CN101969951B (zh) 2012-10-31
KR101585848B1 (ko) 2016-01-15
AU2008322595A1 (en) 2009-05-22
MX2010005395A (es) 2010-06-02
IL205501A0 (en) 2010-12-30
JP2014065716A (ja) 2014-04-17
RU2010123796A (ru) 2011-12-27
CN101969951A (zh) 2011-02-09
WO2009064938A1 (en) 2009-05-22
RU2526201C2 (ru) 2014-08-20
AU2008322595B2 (en) 2014-01-30
JP5667684B2 (ja) 2015-02-12
NZ585085A (en) 2012-08-31
EP2231159A1 (en) 2010-09-29
RU2012143212A (ru) 2014-04-20
JP5450434B2 (ja) 2014-03-26
KR20100099172A (ko) 2010-09-10
RU2472509C2 (ru) 2013-01-20
DOP2013000169A (es) 2013-12-15
US20160101109A1 (en) 2016-04-14
WO2009064938A9 (en) 2009-08-06
US20090176785A1 (en) 2009-07-09
CA2705294A1 (en) 2009-05-22
JP2011503199A (ja) 2011-01-27
IL227641A0 (en) 2013-09-30
CA2705294C (en) 2016-05-17
NZ601350A (en) 2013-08-30
ZA201003434B (en) 2011-10-26

Similar Documents

Publication Publication Date Title
IL205501A (en) Preparation of preparations for the treatment of arthritis
US20080182845A1 (en) Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
CA2662320A1 (en) Bcl inhibitors treating platelet excess
RU2650895C2 (ru) Соединения замещенных пиразолонов и способы использования
AU2016243631B2 (en) Methods of administering glutaminase inhibitors
IL175609A (en) N-acylsulfonamide apoptosis promoters for use in treating diseases during which anti-apoptotic protein family members are expressed
WO2009109610A1 (en) Use of nad information inhibitors for the treatment of ischemia-reperfusion injury
US20160175316A1 (en) Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
RU2672910C2 (ru) Гетероароматические соединения как модуляторы фосфоинозитид-3-киназы
JP6749422B2 (ja) プロテインキナーゼ阻害剤である新規な2,3,5−置換チオフェン化合物
RU2012116877A (ru) Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы
JP2005538099A5 (https=)
JPS6143113A (ja) 医薬組成物
JP2018507257A5 (https=)
RU2013130878A (ru) Гидроксилированные производные аминотриазола в качестве агонистов рецептора alx
RU2012146874A (ru) Производные пиразолопиридина
WO2021201201A1 (ja) 新型コロナウイルス感染症(covid-19)の予防または治療剤および医薬組成物
JP2010513489A5 (https=)
EP3891154A1 (en) 5-hydroxy-7-oxabicyclo[2.2.1]heptane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage
JPWO2019164949A5 (https=)
TW200509915A (en) Novel oxazoles, their manufacture and use as pharmaceutical agents
TW202136237A (zh) RORγt抑制劑及其製備方法和用途
JP2008543770A (ja) (5z)−5−(6−キノキサリニルメチリデン)−2−[(2,6−ジクロロフェニル)アミノ]−1,3−チアゾール−4(5h)−オン
RU2024113309A (ru) Производные пирролидина в качестве ингибиторов ddr
JPWO2022130175A5 (https=)

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees